Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

27. September 2016 16:15 ET | Quelle: Galectin Therapeutics

Galectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot Trial (NASH-FX) with GR-MD-02 in NASH Patients with Advanced Fibrosis

Larger Phase 2b clinical trial in NASH cirrhosis (NASH-CX) now completely enrolled Closed private placement financing for $1.5 million Conference call to be held today at 5:30 p.m. (Eastern Time) ...
31. August 2016 08:00 ET | Quelle: Galectin Therapeutics

Galectin Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference

NORCROSS, Ga., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer,...
25. August 2016 08:00 ET | Quelle: Galectin Therapeutics

Galectin Therapeutics Announces Results From 12-Week Extension of Phase 2a Psoriasis Clinical Trial

NORCROSS, Ga., Aug. 25, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announces interim results from an...
09. August 2016 08:00 ET | Quelle: Galectin Therapeutics

Galectin Therapeutics Reports Second Quarter 2016 Financial Results and Provides Business Update

Top-line data from NASH-FX trial in NASH patients with advanced fibrosis expected to be reported by the end of September Australian patent allowance strengthens global intellectual property...
02. August 2016 08:45 ET | Quelle: Galectin Therapeutics

Galectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Cirrhosis

NORCROSS, Ga., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer,...
02. Juni 2016 08:00 ET | Quelle: Galectin Therapeutics Inc.

Galectin Therapeutics Announces Positive Preclinical Results on the Role of Galectin-3 in Mediating Vascular Remodeling in Pulmonary Arterial Hypertension

NORCROSS, Ga., June 02, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer,...
16. Mai 2016 16:05 ET | Quelle: Galectin Therapeutics Inc.

Galectin Therapeutics Announces Positive Interim Results from Phase 2a Trial with GR-MD-02 in Moderate-to-Severe Plaque Psoriasis

A significant clearing of psoriasis in first four patients prompts the extension of treatment for an additional 12 weeks Conference call to be held tomorrow at 9:00 a.m. Eastern time NORCROSS,...
11. Mai 2016 08:00 ET | Quelle: Galectin Therapeutics Inc.

Galectin Therapeutics Announces Complete Enrollment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Advanced Fibrosis

NORCROSS, Ga., May 11, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer,...
10. Mai 2016 08:00 ET | Quelle: Galectin Therapeutics Inc.

Galectin Therapeutics Reports First Quarter 2016 Financial Results and Provides Business Update

NORCROSS, Ga., May 10, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...
05. Mai 2016 08:00 ET | Quelle: Galectin Therapeutics Inc.

Preclinical Research on the Role of Galectin-3 in Pulmonary Arterial Hypertension to be Presented at the American Thoracic Society 2016 International Conference

NORCROSS, Ga., May 05, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, has...

Vorherige Seite